• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Research and development > Portfolio

Visceral leishmaniasis 

New VL treatments (Latin America)

Home > Research and development > Portfolio

Visceral leishmaniasis

New VL treatments (Latin America)

objective

Assess the safety and efficacy of safer alternatives to the current standard visceral leishmaniasis treatment in Brazil

project start
2011
project status
Treatment delivered in 2022

current phase of drug development

Discovery project phase
Drug Discovery
Translation project phase
Translational research
clinical trials icon
Clinical trials
Treatment Access
Registration & access

updated 15 Feb 2023

Shorter and safer visceral leishmaniasis first-line treatment for people in the Americas

More accessible treatment recommended by PAHO

Until recently, first-line treatment recommendations for visceral leishmaniasis in Brazil included the use of meglumine antimoniate, which presents serious patient management limitations due to toxicity, parenteral administration, and the need for hospitalization.

Starting in 2011, a multicentre, randomized, open label, controlled trial was conducted in five sites in Brazil to evaluate the efficacy and safety of various treatment options compared to the standard, antimonial-based treatment. The collaborative study was sponsored by the Brazilian Ministry of Health and coordinated by the University of Brasilia, the Oswaldo Cruz Foundation of Brazil, and DNDi. Results showed that due to lower toxicity and acceptable efficacy, liposomal amphotericin B was a more suitable first-line treatment for visceral leishmaniasis than standard treatment. This treatment is more accessible for people because of its shorter duration, fewer side effects and reduced hospitalization time.

In 2013, based on the interim safety data from the trial, Brazil’s national guidelines for visceral leishmaniasis were revised to include treatment with liposomal amphotericin B for some patients.

In June 2022, the Pan American Health Organization (PAHO) published new guidelines recommending liposomal amphotericin B instead of pentavalent antimonials.

Treatment regimens

  • Indication: Visceral leishmaniasis in the Americas
  • Dosage: Liposomal amphotericin B given intravenously for 7 days

Impact

  • Changed the recommendation of first-line treatment for visceral leishmaniasis in PAHO’s guidelines replacing the antimonial-based treatment by liposomal amphotericin B, a shorter and safer treatment.
  • The PAHO guidelines can help national programmes strengthen and expand diagnosis and treatment for people affected by this neglected disease.

‘The Ministries of Health, through their respective technical areas and with the support of local experts, should revise the recommendations in the national context and determine the possibility of incorporating, guaranteeing and expanding patient access to treatment of leishmaniasis using safer and shorter-term therapeutic alternatives.’

Ana Nilce Silveira Maia-Elkhoury, Regional Advisor for Leishmaniasis, PAHO/WHO

Project updates

2022

The Pan American Health Organization published new guidelines for the treatment of visceral leishmaniasis in the Americas in June 2022, effectively ending treatment with pentavalent antimonials in favour of less toxic drugs. The new guidelines recommend liposomal amphotericin B as first-line treatment for the disease.

2020

The Brazilian Ministry of Health is reviewing its treatment policy to consider the adoption of liposomal amphotericin B as the country’s first-line visceral leishmaniasis treatment. In addition, the evidence for leishmaniasis treatment in the Americas will be revised by the WHO Guideline Development Group (GDG) in 2021, with the expectation that liposomal amphotericin B will be adopted in the new guidelines.

2019

The Brazilian Ministry of Health is reviewing its treatment policy to consider the adoption of liposomal amphotericin B as the country’s first-line visceral leishmaniasis treatment.

2018

The Brazilian Ministry of Health is still reviewing its treatment policy to consider the adoption of liposomal amphotericin B as the country’s first-line visceral leishmaniasis treatment.

2017

The Brazilian Ministry of Health is reviewing its policy with regard to the adoption of liposomal amphotericin B as first-line treatment for visceral leishmaniasis.

2016

The final results of this trial were presented to the Ministry of Health, and are expected to guide further policy change in Brazil as of 2017.

News & resources

  • 15 December 2022 – Leishmaniasis breakthrough year: new treatments, research, and partnerships
  • 10 October 2022 – The world versus leishmaniasis, The Medicine Maker
  • 29 June 2022 – DNDi welcomes new PAHO recommendations for the treatment of leishmaniasis in the Americas
  • 4 July 2017 – Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial, PLOS Neglected Tropical Diseases

Partners

  • Brasilia University, Brazil
  • Hospital Sao José de Doencas Infecciosas, Brazil
  • Instituto René Rachou (IRR) – Fiocruz Minas, Brazil
  • Ministry of Health Brazil, Leishmaniasis Control Programme, Brazil
  • Montes Claros State University, Brazil
  • Paediatric Hospital Joao Paulo II – FHEMIG, Brazil
  • Piaui Federal University, Brazil
  • Sergipe Federal University, Brazil
  • Universidade Estadual do Rio de Janeiro, Brazil
Loading…
  • Brasilia University
  • ,Brazil
  • Hospital Sao José de Doencas Infecciosas
  • ,Brazil
  • Instituto René Rachou (IRR) – Fiocruz Minas
  • ,Brazil
  • Ministry of Health Brazil, Leishmaniasis Control Programme
  • ,Brazil
  • Montes Claros State University
  • ,Brazil
  • Paediatric Hospital Joao Paulo II – FHEMIG
  • ,Brazil
  • Piaui Federal University
  • ,Brazil
  • Sergipe Federal University
  • ,Brazil
  • Universidade Estadual do Rio de Janeiro
  • ,Brazil
  • Brasilia University, Brazil
  • Hospital Sao José de Doencas Infecciosas, Brazil
  • Ministry of Health Brazil, Leishmaniasis Control Programme, Brazil
  • Montes Claros State University, Brazil
  • Paediatric Hospital Joao Paulo II – FHEMIG, Brazil
  • Piaui Federal University, Brazil
  • Instituto René Rachou (IRR) – Fiocruz Minas, Brazil
  • Sergipe Federal University, Brazil
  • Universidade Estadual do Rio de Janeiro, Brazil

Funding

  • Brazil - Science and Technology Innovation Agency (Finep)/ Through the Regional and National Finep Awards for Innovation in Social Technology
  • Brazil - Ministry of Health Brazil
  • Germany - Federal Ministry for Economic Cooperation and Development (BMZ) through KfW
  • Norway - Norwegian Government
  • Spain - Spanish Agency for International Development Cooperation (AECID)
  • Switzerland - Swiss Agency for Development and Cooperation (SDC)
  • UK - UK International Development
​
  • Bem-Te-Vi Diversidade
  • Medicor Foundation
  • Médecins Sans Frontières International
  • Other private foundations and individuals
​

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License